While CD5-positive DLBCL is broadly associated with aggressive features (e.g., non-GCB phenotype, extranodal/CNS spread, and rituximab resistance) [5], its prognostic impact in PBM-DLBCL remains unvalidated due to limited cases. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.